| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
36,750,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repare Therapeutics is a precision medicine oncology company focused on the development of synthetic lethality (SL)-based therapies to patients with cancer. Using Co.'s SNIPRx platform, Co. is developing its pipeline of SL product candidates, including its primary product candidate, RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ATM gene (ataxia telangiectasia mutated kinase). Co. is also developing an inhibitor of polymerase theta, which is SL with multiple gene deficiencies found in tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,227,301 |
1,227,301 |
3,633,420 |
| Total Buy Value |
$0 |
$6,249,889 |
$6,249,889 |
$33,578,038 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
2 |
2 |
7 |
| Total Shares Sold |
21,690 |
21,690 |
32,163 |
2,532,163 |
| Total Sell Value |
$101,066 |
$101,066 |
$227,039 |
$31,793,364 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
20 |
23 |
27 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
10% Owner |
– – • |
2023-11-16 |
4 |
B |
$5.38 |
$1,592,202 |
D/D |
295,745 |
548,938 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2023-11-15 |
4 |
B |
$5.00 |
$4,657,687 |
D/D |
931,556 |
532,795 |
2.45 |
- |
|
| Zinda Michael |
EVP, Chief Scientific Officer |
• – – |
2023-06-08 |
4 |
S |
$12.02 |
$34,485 |
D/D |
(2,869) |
60,118 |
|
- |
|
| Zinda Michael |
EVP, Chief Scientific Officer |
• – – |
2023-06-07 |
4 |
AS |
$12.03 |
$77,040 |
D/D |
(6,404) |
62,987 |
|
- |
|
| Zinda Michael |
EVP, Chief Scientific Officer |
• – – |
2023-06-06 |
4 |
AS |
$12.04 |
$14,448 |
D/D |
(1,200) |
69,391 |
|
- |
|
| Segal Lloyd Mitchell |
President and CEO |
• • – |
2023-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
78,550 |
84,677 |
|
- |
|
| Koehler Maria |
EVP, Chief Medical Officer |
• – – |
2023-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
26,450 |
175,963 |
|
- |
|
| Forte Steve |
EVP, Chief Financial Officer |
• – – |
2023-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
24,530 |
30,687 |
|
- |
|
| Zinda Michael |
EVP, Chief Scientific Officer |
• – – |
2023-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
24,550 |
70,591 |
|
- |
|
| Jerel Davis |
Director |
– • – |
2022-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
4,254 |
25,131 |
|
- |
|
| Jerel Davis |
Director |
– • – |
2022-12-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(397,888) |
0 |
|
- |
|
| Jerel Davis |
Director |
– • – |
2022-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
70,678 |
4,721 |
|
- |
|
| Koehler Maria |
EVP, Chief Medical Officer |
• – – |
2022-12-20 |
4 |
OE |
$2.06 |
$100,040 |
D/D |
48,507 |
149,513 |
|
- |
|
| Jerel Davis |
Director |
– • – |
2022-12-09 |
4 |
S |
$16.00 |
$4,000,000 |
I/I |
(250,000) |
2,094,451 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2022-06-13 |
4 |
B |
$12.73 |
$1,898,820 |
D/D |
149,161 |
412,604 |
2.45 |
- |
|
| Versant Vantage I Gp-Gp, Llc |
10% Owner |
– – • |
2022-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(851,202) |
0 |
|
- |
|
| Versant Vantage I Gp-Gp, Llc |
10% Owner |
– – • |
2022-06-06 |
4 |
A |
$0.00 |
$0 |
I/I |
151,202 |
10,099 |
|
- |
|
| Jerel Davis |
Director |
– • • |
2022-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,101 |
20,877 |
|
- |
|
| Jerel Davis |
Director |
– • • |
2022-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(851,202) |
0 |
|
- |
|
| Jerel Davis |
Director |
– • • |
2022-06-06 |
4 |
A |
$0.00 |
$0 |
I/I |
151,202 |
10,099 |
|
- |
|
| Versant Ventures V (canada), L.p. |
10% Owner |
– – • |
2022-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(710,099) |
0 |
|
- |
|
| Versant Ventures V (canada), L.p. |
10% Owner |
– – • |
2022-06-06 |
4 |
A |
$0.00 |
$0 |
I/I |
10,099 |
10,099 |
|
- |
|
| Versant Ventures V (canada), L.p. |
10% Owner |
– – • |
2022-06-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(141,103) |
0 |
|
- |
|
| Versant Ventures V (canada), L.p. |
10% Owner |
– – • |
2022-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
141,103 |
141,103 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2022-06-06 |
4 |
B |
$13.21 |
$90,752 |
D/D |
6,869 |
406,436 |
2.45 |
- |
|
260 Records found
|
|
Page 2 of 11 |
|
|
